Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2023-12-19 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
董事会审计委员会工作细则（2023年12月）
Governance Information Classification · 100% confidence The document is titled '云南沃森生物技术股份有限公司 董事会审计委员会工作细则' which translates to 'Yunnan Watson Biotechnology Co., Ltd. Board Audit Committee Working Rules'. It details the structure, responsibilities, meeting procedures, and governance of the company's audit committee. There is no financial data, no report of financial results, no announcement of voting results, no executive changes, no legal proceedings, no capital changes, and no earnings or annual report content. The document is a governance-related internal rules document about the audit committee's operation and responsibilities, which fits the definition of Governance Information (CGR). The document length is 2500 characters, which is relatively short but contains substantive governance content rather than a mere announcement. Therefore, the correct classification is Governance Information (CGR).
2023-12-19 Chinese
关于放弃控股子公司股权转让优先购买权并签署相关协议的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the company's decision to waive its preemptive rights to purchase shares in its controlled subsidiary and the signing of related share transfer agreements. It includes comprehensive information about the transaction parties, shareholding structure before and after the transfer, terms of the share transfer agreement, payment terms, conditions precedent, warranties, breach liabilities, and board authorizations. The document is not a financial report, earnings release, or management discussion but a formal announcement of a capital transaction involving share transfer and waiver of preemptive rights. It does not present financial statements or audit opinions but focuses on the share transfer and related agreements. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as share transfers and waivers of purchase rights.
2023-12-19 Chinese
第五届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the fifteenth meeting of the fifth board of directors of Yunnan Watson Biotechnology Co., Ltd. It details decisions on waiving preemptive rights on subsidiary share transfers and amendments to various board committee working rules. The document includes voting results and references to related documents available on the regulatory disclosure website. There is no financial data, earnings information, or report publication notice. The content focuses on board decisions and governance matters, specifically changes to board committee rules and approvals related to shareholding in a subsidiary. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2023-12-19 Chinese
董事会提名委员会工作细则（2023年12月）
Governance Information Classification · 95% confidence The document is titled '云南沃森生物技术股份有限公司 董事会提名委员会工作细则' which translates to 'Yunnan Watson Biotechnology Co., Ltd. Board Nomination Committee Working Rules'. It details the structure, responsibilities, procedures, and rules of the Board Nomination Committee. There is no financial data, no mention of financial results, no voting results, no announcements of reports, or any other regulatory filings. The content is focused on governance practices related to the board and senior management nomination process. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 2516 characters, which is sufficient for a detailed governance document. Therefore, the classification is CGR with high confidence.
2023-12-19 Chinese
关于全资子公司完成工商变更登记的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of a business registration change for a wholly-owned subsidiary of the company, including details about capital increase and updated business license information. It does not contain financial statements, management discussion, or detailed financial data. The document is relatively short (856 characters) and serves as a formal notification of a corporate event related to capital increase and registration update. This fits best under Capital/Financing Update (CAP) as it relates to the company's financing activities and capital structure changes through subsidiary capital increase.
2023-12-13 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase plan. It details the number of shares repurchased, prices, compliance with regulatory guidelines, and the timeline of the repurchase activities. It references specific regulatory rules about share buybacks and provides updates on the repurchase progress. The document length is short (1941 characters) and it is not a full financial report but an update on share repurchase activity. Therefore, it fits the category of Transaction in Own Shares (POS).
2023-12-04 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.